Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | USP5 | P45974 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28096680 | 0.88 | HDAC1 (0.46) | QDPRHDAC1HDAC2HDAC3IDO1 | |
| SCHEMBL16262649 | 0.86 | HDAC1 (0.49) | QDPRHDAC1HDAC2HDAC3NPC1 | |
| SCHEMBL3418716 | 0.86 | USP5 (0.50) | QDPRIDO1NPC1USP5HDAC6 | |
| SCHEMBL23122328 | 0.84 | QDPR (0.56) | QDPRHDAC1HDAC2HDAC3 | |
| SCHEMBL4725995 | 0.82 | IDO1 (0.56) | QDPRIDO1USP5HDAC6CCR2 | |
| SCHEMBL25430208 | 0.81 | QDPR (0.56) | QDPRIDO1NPC1USP5HDAC6 | |
| SCHEMBL23122840 | 0.81 | QDPR (0.56) | QDPRHDAC1HDAC2HDAC3 | |
| SCHEMBL3988015 | 0.80 | DPP4 (0.52) | — | |
| SCHEMBL16318326 | 0.80 | QDPR (0.43) | QDPRHDAC1HDAC2HDAC3CCR1 | |
| SCHEMBL4782539 | 0.79 | IDO1 (0.47) | QDPRIDO1NPC1USP5HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1708704-A4 | 4-ARYL PIPERIDINES | LUNDBECK & CO AS H (DK) | 2009-08-05 | — | — | EP | disclosed |
| EP-1799223-A4 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | LUNDBECK & CO AS H (DK) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007114916-A2 | ARYLBENZYLPIPERIDINE COMPOUNDS | H. LUNDBECK A/S (DK) | 2007-10-11 | — | — | WO | disclosed |
| EP-1799223-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATES | H.Lundbeck A/S (DK) | 2007-06-27 | — | — | EP | disclosed |
| EP-1708704-A2 | 4-ARYL PIPERIDINES | H.Lundbeck A/S (DK) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006041635-A2 | ARYLTHIOBENZYLPIPERIDINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005069834-A2 | 4-ARYL PIPERIDINES | H. LUNDBECK A/S (DK) | 2005-08-04 | — | — | WO | disclosed |
| US-20050154022-A1 | 4-aryl piperidines | H. LUNDBECK A/S | 2005-07-14 | — | — | US | disclosed |
| US-20050154020-A1 | 4-Aryl piperidines | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154022-A1 | 4-aryl piperidines | MCHR1, MCHR2, MC1R | QDPR 221/4885HDAC1 2020/4885HDAC2 1955/4885 |
| US-20050154020-A1 | 4-Aryl piperidines | MCHR1, MCHR2, MC1R | QDPR 221/4885HDAC1 2020/4885HDAC2 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.